ERCC1 rs3212986 A/C polymorphism is not associated with chemotherapy treatment outcomes in gastric cancer patients: evidence from 11 publications in Chinese populations

作者：Tang, Weiwei; Wang, Hanjin; Wang, Yuemei^*; Wang, Xiaowei^*

来源：OncoTargets and Therapy, 2018, 11: 1-8.

DOI：10.2147/OTT.S148214

• ERCC1
• rs3212986
• cancer
• polymorphism
• meta-analysis
• survival
• prognoses

Background: A number of studies have investigated the roles of excision repair cross-complementation group 1 (ERCC1) gene rs3212986 polymorphisms as potential biomarkers in gastric cancer (GC). However, the results were inconsistent. Here, we performed a metaanalysis to explore ERCC1 rs3212986 polymorphisms in the chemotherapy response and clinical outcome of GC. @@@ Methods: PubMed, Embase, and Web of Science were searched up to July 28, 2017, for studies on the association between ERCC1 rs3212986 A/C polymorphisms and response to chemotherapy as well as overall survival time of GC. A fixed-effect or random-effect model was used to calculate the pooled odds ratios (ORs) based on the results from the heterogeneity tests. @@@ Results: The result revealed that there was no significant association between the ERCC1 rs3212986 A/C polymorphism and response to chemotherapy in GC under comparison models (AA + CA versus CC, OR 0.95, P= 0.80, AA versus CA, OR 0.85, P= 0.55, AA versus CC, OR 0.74, P= 0.47). Further identification suggested that ERCC1 rs3212986 A/C polymorphisms were not linked with the overall survival of GC (AA + CA versus CC, OR 1.09, P= 0.52, AA versus CA, OR 1.05, P= 0.85, AA versus CC, OR 1.43, P= 0.23). @@@ Conclusion: Our meta-analysis indicated that the ERCC1 rs3212986 A/C polymorphism was not associated with response to chemotherapy or overall survival time in GC. Well-designed studies with larger sample sizes and more ethnic groups should be performed to further validate our results.

• 出版日期2018
• 单位南京医科大学